{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:40:39Z","timestamp":1720528839960},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81101297"],"award-info":[{"award-number":["81101297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.meegid.2015.05.014","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T13:12:13Z","timestamp":1431609133000},"page":"269-276","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response"],"prefix":"10.1016","volume":"33","author":[{"given":"Yu-Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Xiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Lan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.meegid.2015.05.014_b0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jir821","article-title":"Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing","volume":"205","author":"Armenia","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.meegid.2015.05.014_b0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2008.12.018","article-title":"Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy","volume":"50","author":"Chen","year":"2009","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.meegid.2015.05.014_b0015","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JCM.00850-11","article-title":"Evaluation of high-throughput sequencing for identifying known and unknown viruses in biological samples","volume":"49","author":"Cheval","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.meegid.2015.05.014_b0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.antiviral.2014.09.013","article-title":"Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B","volume":"112","author":"Cho","year":"2014","journal-title":"Antiviral Res."},{"issue":"17","key":"10.1016\/j.meegid.2015.05.014_b0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.meegid.2015.05.014_b0030","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/JCM.01723-13","article-title":"Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity","volume":"51","author":"Gong","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"9","key":"10.1016\/j.meegid.2015.05.014_b0035","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"42","key":"10.1016\/j.meegid.2015.05.014_b0040","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.3748\/wjg.v18.i42.6096","article-title":"Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing","volume":"18","author":"Homs","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.meegid.2015.05.014_b0045","doi-asserted-by":"crossref","first-page":"E404","DOI":"10.1111\/j.1469-0691.2012.03951.x","article-title":"Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing","volume":"18","author":"Ko","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.meegid.2015.05.014_b0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.meegid.2015.05.014_b0055","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.meegid.2015.05.014_b0060","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.meegid.2015.05.014_b0065","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.meegid.2015.05.014_b0070","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1128\/AAC.01742-13","article-title":"Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.meegid.2015.05.014_b0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1478-3231.2008.01941.x","article-title":"Natural history of chronic hepatitis B virus infection and long-term outcome under treatment","volume":"29","author":"Liaw","year":"2009","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.meegid.2015.05.014_b0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1053\/j.gastro.2007.06.011","article-title":"Viral quasi-species evolution during hepatitis Be antigen seroconversion","volume":"133","author":"Lim","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.meegid.2015.05.014_b0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistance in patients with chronic hepatitis B","volume":"9","author":"Locarnini","year":"2004","journal-title":"Antiviral Ther."},{"issue":"2","key":"10.1016\/j.meegid.2015.05.014_b0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.meegid.2015.05.014_b0095","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.meegid.2015.05.014_b0100","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.meegid.2015.05.014_b0105","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/597808","article-title":"Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients","volume":"199","author":"Margeridon-Thermet","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"5 Suppl.","key":"10.1016\/j.meegid.2015.05.014_b0110","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","author":"McMahon","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.meegid.2015.05.014_b0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virol.2012.01.002","article-title":"Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients","volume":"426","author":"Messiaen","year":"2012","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.meegid.2015.05.014_b0120","doi-asserted-by":"crossref","first-page":"e35052","DOI":"10.1371\/journal.pone.0035052","article-title":"Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing","volume":"7","author":"Nishijima","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.meegid.2015.05.014_b0125","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.meegid.2015.05.014_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.22634","article-title":"Complex dynamics of hepatitis B virus resistance to adefovir","volume":"49","author":"Pallier","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.meegid.2015.05.014_b0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.meegid.2015.05.014_b0140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.meegid.2015.05.014_b0145","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep.26383","article-title":"Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing","volume":"58","author":"Rodriguez","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.meegid.2015.05.014_b0150","doi-asserted-by":"crossref","first-page":"e37874","DOI":"10.1371\/journal.pone.0037874","article-title":"Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome","volume":"7","author":"Rodriguez-Frias","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.meegid.2015.05.014_b0155","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/hep.26647","article-title":"Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: resolving the nitty-gritty","volume":"59","author":"Rodriguez-Frias","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.meegid.2015.05.014_b0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.antiviral.2012.03.003","article-title":"Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes","volume":"94","author":"Sede","year":"2012","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.meegid.2015.05.014_b0165","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.meegid.2015.05.014_b0170","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/JVI.02011-08","article-title":"Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen","volume":"83","author":"Solmone","year":"2009","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.meegid.2015.05.014_b0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3350\/kjhep.2011.17.4.268","article-title":"Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B","volume":"17","author":"Song","year":"2011","journal-title":"Korean J. Hepatol."},{"issue":"4","key":"10.1016\/j.meegid.2015.05.014_b0180","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.meegid.2015.05.014_b0185","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/jhep.2001.22166","article-title":"Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region","volume":"33","author":"Stuyver","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2015.05.014_b0190","article-title":"Guidelines for avoiding risks resulting from discontinuation of nucleoside\/nucleotide analogs in patients with chronic hepatitis B","author":"Tanaka","year":"2013","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.meegid.2015.05.014_b0195","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ncomms1794","article-title":"Convergence and coevolution of hepatitis B virus drug resistance","volume":"3","author":"Thai","year":"2012","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.meegid.2015.05.014_b0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00535-012-0668-y","article-title":"Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog","volume":"48","author":"Tseng","year":"2013","journal-title":"J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.meegid.2015.05.014_b0205","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/hep.21939","article-title":"Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response","volume":"46","author":"Yuen","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.meegid.2015.05.014_b0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcv.2013.04.003","article-title":"Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B","volume":"57","author":"Zhu","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.meegid.2015.05.014_b0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","article-title":"Regularization and variable selection via the elastic net","volume":"67","author":"Zou","year":"2005","journal-title":"J. R. Stat. Soc. Ser. B Stat. Meth."},{"issue":"5","key":"10.1016\/j.meegid.2015.05.014_b0220","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134815001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134815001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T23:55:33Z","timestamp":1651967733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134815001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":44,"alternative-id":["S1567134815001768"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2015.05.014","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2015.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}